The recommended dosage regimen for Tygacil is an initial dose of 100 mg, followed by 50 mg every 12 hrs. IV infusions of Tygacil should be administered over approximately 30-60 min every 12 hrs.
The recommended duration of treatment with Tygacil for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5-14 days. The duration of therapy should be guided by the severity and site of the infection and the patient's clinical and bacteriological progress.
Hepatic Impairment: No dosage adjustment is warranted in patients with mild to moderate hepatic impairment (Child-Pugh A and Child-Pugh B). In patients with severe hepatic impairment (Child-Pugh C), the dose of Tygacil should be reduced to 100 mg followed by 25 mg every 12 hrs. Patients with severe hepatic impairment (Child-Pugh C) should be treated with caution and monitored for treatment response. (See Pharmacokinetics: Special Populations under Actions and Use in Patients with Hepatic Impairment under Precautions.)
Renal Impairment: No dosage adjustment of Tygacil is necessary in patients with renal impairment or in patients undergoing hemodialysis. (See Pharmacokinetics: Special Populations and Use in Patients with Renal Impairment under Actions.)
Children: Safety and effectiveness in patients <18 years have not been established. Therefore, use in patients <18 years is not recommended. (See Warnings.)
No dosage adjustment of Tygacil is necessary based on age, gender or race. (See Pharmacokinetics: Special Populations under Actions and Use in the elderly under Precautions.)